Shield Therapeutics plc
STX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £25,184 | £13,085 | £5,499 | £1,519 |
| % Growth | 92.5% | 138% | 262% | – |
| Cost of Goods Sold | £14,615 | £9,058 | £2,470 | £980 |
| Gross Profit | £10,569 | £4,027 | £1,997 | £539 |
| % Margin | 42% | 30.8% | 36.3% | 35.5% |
| R&D Expenses | £1,477 | £1,810 | £1,072 | £579 |
| G&A Expenses | £10,759 | £15,172 | £27,331 | £20,023 |
| SG&A Expenses | £27,068 | £36,889 | £27,331 | £20,023 |
| Sales & Mktg Exp. | £23,829 | £21,717 | £0 | £0 |
| Other Operating Expenses | £9,258 | -£3,341 | -£700 | -£111 |
| Operating Expenses | £37,803 | £35,358 | £27,703 | £20,491 |
| Operating Income | -£17,976 | -£31,331 | -£26,391 | -£20,405 |
| % Margin | -71.4% | -239.4% | -479.9% | -1,343.3% |
| Other Income/Exp. Net | -£2,806 | -£1,044 | -£13,667 | £498 |
| Pre-Tax Income | -£20,782 | -£32,375 | -£40,082 | -£19,907 |
| Tax Expense | £490 | £918 | £446 | -£229 |
| Net Income | -£21,272 | -£33,293 | -£40,444 | -£19,336 |
| % Margin | -84.5% | -254.4% | -735.5% | -1,272.9% |
| EPS | -0.024 | -0.037 | -0.17 | -0.095 |
| % Growth | 36.7% | 78.2% | -79.7% | – |
| EPS Diluted | -0.024 | -0.037 | -0.17 | -0.095 |
| Weighted Avg Shares Out | 905,204 | 722,544 | 233,190 | 204,410 |
| Weighted Avg Shares Out Dil | 905,204 | 722,544 | 233,190 | 204,410 |
| Supplemental Information | – | – | – | – |
| Interest Income | £208 | £417 | £30 | £13 |
| Interest Expense | £3,090 | £820 | £334 | £8 |
| Depreciation & Amortization | £1,115 | £1,071 | £2,873 | £2,207 |
| EBITDA | -£16,577 | -£30,288 | -£46,067 | -£17,692 |
| % Margin | -65.8% | -231.5% | -837.7% | -1,164.7% |